<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1798">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528927</url>
  </required_header>
  <id_info>
    <org_study_id>ECC2020-05</org_study_id>
    <nct_id>NCT04528927</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia</brief_title>
  <acronym>THINC</acronym>
  <official_title>Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abderrahmane Mami Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eshmoun Clinical Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datametrix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abderrahmane Mami Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19
      Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized
      Comparative Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm 1:

        -  Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 /D
           for 9 days

        -  Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days

        -  Usual standard treatment

      Arm 2:

        -  HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days

        -  Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days

        -  Zinc: 220 mg per day for 10 days

        -  Usual standard treatment

      Arm 3:

        -  Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days

        -  Doxycycline: 200 mg per day for 10 days.

        -  Usual standard treatment
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    - Interest in the use of HCQ is controversial.
  </why_stopped>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of patients cured at the end of the study.</measure>
    <time_frame>2 months</time_frame>
    <description>The healing criteria are defined clinically as:
disappearance of clinical signs of acute respiratory infection absence of fever</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the rate of patients are pauci-symptomatic at the end of the study.</measure>
    <time_frame>2 months</time_frame>
    <description>A patient will be defined as pauci-symptomatic if presence:
Light dry cough
Discomfort,
More or less :
Headache,
Muscle pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the rate of patients with worsening clinical signs</measure>
    <time_frame>2 months</time_frame>
    <description>Patients require transfer to intensive care with the appearance of:
Acute respiratory failure: PaO2 &lt;60 mmHg in AA gold
Signs of circulatory insufficiency: mottling, tachycardia, systolic BP â‰¤90mmHg or having dropped by 40 mmHg compared to base BP or
Confusion or alteration of the state of consciousness</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID 19</condition>
  <condition>Patients Hospitalized</condition>
  <arm_group>
    <arm_group_label>HCQ+Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
Usual standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCQ+Azithromycin+Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
Zinc: 220 mg per day for 10 days
Usual standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin+Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
Doxycycline: 200 mg per day for 10 days.
Usual standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCQ</intervention_name>
    <description>600 mg on the 1st day as a starting dose then 200 mg * 2 /D for 9 days</description>
    <arm_group_label>HCQ+Azithromycin</arm_group_label>
    <arm_group_label>HCQ+Azithromycin+Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg (1st day) then 250 mg / D for 4 days</description>
    <arm_group_label>Azithromycin+Doxycycline</arm_group_label>
    <arm_group_label>HCQ+Azithromycin</arm_group_label>
    <arm_group_label>HCQ+Azithromycin+Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>200 mg per day for 10 days</description>
    <arm_group_label>Azithromycin+Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>220 mg per day for 10 days</description>
    <arm_group_label>HCQ+Azithromycin+Zinc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed patient COVID19 positive with clinical signs of acute lower respiratory
             infection with signs of pneumonia or bronchitis: fever and / or cough and / or
             difficulty breathing in the absence of acute respiratory failure (PaO2&gt; 60 mmHg) with
             Plus or less :

               -  Chills

               -  Asthenia, fatigability

               -  Headache

               -  Arthromas myalgia

               -  Dry throat

               -  Rhinorrhea

               -  An anosmia

               -  chest pain

               -  Diarrhea

               -  Nausea and vomiting

                    -  Absence of rhythm disturbance (Qt interval &lt;500ms)

                    -  Patients hospitalized in the medical service

                    -  18 years old &lt;Age &lt;80 years old

                    -  Having given written consent for their participation in the study

        Exclusion Criteria:

          -  Allergy to macrolides, local anesthetics such as lidocaine or amide type and
             betalactamines

          -  Take hydroxychloquine in the previous month

          -  Severe / severe liver failure

          -  Kidney failure (GFR &lt;30 ml / min / 1.73 m2)

          -  Ongoing treatments with colchicine, ergot, rye, pimozide, mizolastine, simvastatin,
             lomitapide, alfuzosin, dapoxetine, avanafil, ivabradine, eplerenone, dronedarone,
             quetiapine, ticagrelor, cisapride, astemizole, terfenadine, ranolazine, domperidone.

          -  Complete branch block

          -  Hypovolemia

          -  Retinopathy including vitreous involvement

          -  Psoriasis

          -  Pregnant or breastfeeding woman

          -  hypersensitivity to chloroquine or hydroxychloroquine or to any of the other
             ingredients of this medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eshmoun Clinical Research Centre</name>
      <address>
        <city>Tunis</city>
        <zip>1053</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Abderrahmane Mami Hospital</investigator_affiliation>
    <investigator_full_name>Dr Jalila Ben Khelil</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

